Satipharm Now Selling CBD Products in German Pharmacies

logo-satipharm

Satipharm Sales Update and Expansion of European Distribution Network

13 March 2017

  • Satipharm’s flagship product, Gelpell-CBD Microgel Capsules, now available for
    sale throughout all pharmaceutical outlets in Germany
  • Strategic partnership with online pharmaceutical reseller enables shipping of
    Satipharm products globally – removing significant payment gateway issues
  • European sales footprint further expanded following signing of binding LOI with
    one of the fastest growing pharmaceutical distributors in Denmark
  • MMJ to work with distribution partners to roll out strategic sales and marketing
    campaign across Europe aimed at boosting brand awareness and product sales

MMJ PhytoTech Limited (ASX: MMJ) (“MMJ” or “the Company”) is pleased to provide the following sales and operations update on its wholly-owned Switzerland-based subsidiary, Satipharm AG (“Satipharm”).

Satipharm has secured Pharmaceutical Central Numbers (PZN codes) for its 10mg and 50mg Gelpell-CBD Microgel Capsules, enabling both products to be sold in all pharmacies
throughout Germany.

The Company’s online distribution partner, German Bodfeld Pharmacy, has commenced the shipping of Satipharm’s cannabidiol (“CBD”) extract products to regulated markets globally, further enhancing the Company’s capacity to rapidly scale up product sales. Importantly, German Bodfeld Pharmacy accepts all major payment methods, which solves a key payment gateway issue imposed on CBD producers globally due to the federal U.S. ban of cannabinoids.

In addition, Satipharm has signed a binding Letter of Intent (“LOI”) with a leading
pharmaceutical distributor and retailer in Denmark for the marketing and distribution of
Satipharm’s products throughout Scandinavia. The Company expects this partnership to
provide direct access to hundreds of thousands of potential new customers, to be targeted through an extensive sales and marketing campaign.

Satipharm’s continued expansion and penetration of key markets in Europe is a key focus for MMJ, and has the capacity to serve as a significant value catalyst for our shareholders in the near-term.

andreas gedeonMMJ PhytoTech’s Managing Director, Andreas Gedeon

The availability of our Gelpell-CBD Microgel Capsules over the counter throughout all German pharmacies is a key milestone, and positions Satipharm as one of the leading CBD suppliers in Europe.

Original press release: http://clients3.weblink.com.au/pdf/MMJ/01838026.pdf

Get ahead of the crowd by signing up for 420 Investor, the largest & most comprehensive premium subscription service for cannabis traders and investors since 2013.

Published by NCV Newswire
NCV Newswire
The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. Have a confidential news tip? Get in touch.

Get Our Sunday Newsletter